117 related articles for article (PubMed ID: 10764960)
1. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
Ott MC; Costain WJ; Mishra RK; Johnson RL
Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
[TBL] [Abstract][Full Text] [Related]
2. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
4. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-pro-L-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes.
Mishra RK; Makman MH; Costain WJ; Nair VD; Johnson RL
Neurosci Lett; 1999 Jul; 269(1):21-4. PubMed ID: 10821635
[TBL] [Abstract][Full Text] [Related]
5. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1).
Marcotte ER; Chugh A; Mishra RK; Johnson RL
Peptides; 1998; 19(2):403-6. PubMed ID: 9493876
[TBL] [Abstract][Full Text] [Related]
6. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
[TBL] [Abstract][Full Text] [Related]
7. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
8. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.
Mishra RK; Srivastava LK; Johnson RL
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):821-7. PubMed ID: 1981396
[TBL] [Abstract][Full Text] [Related]
9. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
Castellano JM; Batrynchuk J; Dolbeare K; Verma V; Mann A; Skoblenick KJ; Johnson RL; Mishra RK
Peptides; 2007 Oct; 28(10):2009-15. PubMed ID: 17766011
[TBL] [Abstract][Full Text] [Related]
10. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum.
Merchant KM
Mol Cell Neurosci; 1994 Aug; 5(4):336-44. PubMed ID: 7804603
[TBL] [Abstract][Full Text] [Related]
11. Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.
Costain WJ; Buckley AT; Evans MC; Mishra RK; Johnson RL
Peptides; 1999; 20(6):761-7. PubMed ID: 10477133
[TBL] [Abstract][Full Text] [Related]
12. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
Chiu S; Paulose CS; Mishra RK
Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
[TBL] [Abstract][Full Text] [Related]
13. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects.
Merchant KM; Hanson GR; Dorsa DM
J Pharmacol Exp Ther; 1994 May; 269(2):806-12. PubMed ID: 8182549
[TBL] [Abstract][Full Text] [Related]
14. Role of NR2B-containing N-methyl-D-aspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens.
Lee J; Rajakumar N
Neuroscience; 2003; 122(3):739-45. PubMed ID: 14622917
[TBL] [Abstract][Full Text] [Related]
15. PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia.
Dyck B; Guest K; Sookram C; Basu D; Johnson R; Mishra RK
Schizophr Res; 2011 Jan; 125(1):88-92. PubMed ID: 21036015
[TBL] [Abstract][Full Text] [Related]
16. Scopolamine attenuates haloperidol-induced c-fos expression in the striatum.
Guo N; Robertson GS; Fibiger HC
Brain Res; 1992 Aug; 588(1):164-7. PubMed ID: 1393566
[TBL] [Abstract][Full Text] [Related]
17. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity.
Marin C; Bonastre M; Tolosa E
Synapse; 1996 Jun; 23(2):89-93. PubMed ID: 8723713
[TBL] [Abstract][Full Text] [Related]
18. The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats.
Daya R; Ho J; Thomson S; Bhandari J; Mishra RK
Curr Mol Pharmacol; 2021 Oct; 14(4):469-476. PubMed ID: 32912130
[TBL] [Abstract][Full Text] [Related]
19. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
Mishra RK; Marcotte ER; Chugh A; Barlas C; Whan D; Johnson RL
Peptides; 1997; 18(8):1209-15. PubMed ID: 9396063
[TBL] [Abstract][Full Text] [Related]
20. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
